Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 0.75 |
| ▸ | SLC6A2 known ✓ | P23975 | 5/20 | 0.51 |
| ▸ | HTR1A known ✓ | P08908 | 3/20 | 0.51 |
| ▸ | SLC6A4 known ✓ | P31645 | 4/20 | 0.50 |
| ▸ | SLC6A3 known ✓ | Q01959 | 3/20 | 0.50 |
| ▸ | PRKCZ known ✓ | Q05513 | 1/20 | 0.49 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.48 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.48 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.63 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL796443 | 1.00 | HRH1 (0.75) | HRH1CHRNB2CHRNA4SLC6A2HTR1A | |
| Hydrochloric Acid SCHEMBL795806 | 1.00 | HRH1 (0.75) | HRH1CHRNB2CHRNA4SLC6A2HTR1A | |
| SCHEMBL14828522 | 0.98 | HRH1 (0.78) | HRH1CHRNB2CHRNA4SLC6A2HTR1A | |
| SCHEMBL2523551 | 0.98 | HRH1 (0.78) | HRH1CHRNB2CHRNA4SLC6A2HTR1A | |
| SCHEMBL226349 | 0.98 | HRH1 (0.78) | HRH1CHRNB2CHRNA4SLC6A2HTR1A | |
| Hydrochloric Acid SCHEMBL4317936 | 0.93 | HRH1 (0.66) | HRH1CHRNB2CHRNA4SLC6A2HTR1A | |
| Hydrochloric Acid SCHEMBL4317942 | 0.93 | HRH1 (0.66) | HRH1CHRNB2CHRNA4SLC6A2HTR1A | |
| SCHEMBL4317978 | 0.91 | HRH1 (0.68) | HRH1CHRNB2CHRNA4SLC6A2HTR1A | |
| SCHEMBL4317973 | 0.91 | HRH1 (0.68) | HRH1CHRNB2CHRNA4SLC6A2HTR1A | |
| Hydrochloric Acid SCHEMBL4443248 | 0.88 | HRH1 (0.96) | HRH1CHRNB2CHRNA4SLC6A2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676926-A1 | BICYCLIC HETEROARYL COMPOUNDS FOR USE AS GPR35 MODULATORS | ThirtyFiveBio Limited (GB) | 2026-01-14 | — | — | EP | disclosed |
| US-12110294-B2 | CD73 compounds | GILEAD SCIENCES, INC. (US) | 2024-10-08 | — | — | US | disclosed |
| WO-2024184650-A1 | BICYCLIC HETEROARYL COMPOUNDS FOR USE AS GPR35 MODULATORS. | ThirtyFiveBio Limited (GB) | 2024-09-12 | — | — | WO | disclosed |
| US-20240043427-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2024-02-08 | — | — | US | disclosed |
| EP-3533797-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2023-12-20 | — | — | EP | disclosed |
| US-20230312542-A1 | HYDROXYPYRROLIDINE DERIVATIVE AND MEDICINAL APPLICATION THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-10-05 | — | — | US | disclosed |
| EP-4143194-A1 | CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20230039553-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| EP-4129402-A1 | HYDROXYPYRROLIDINE DERIVATIVE AND MEDICINAL APPLICATION THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2023-02-08 | — | — | EP | disclosed |
| CN-115698009-A | CD73 inhibiting 2,4-dioxopyrimidine compounds | 吉利德科学公司 | 2023-02-03 | — | — | CN | disclosed |
| US-20140235615-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-21 | — | — | US | disclosed |
| US-20140228352-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-14 | — | — | US | disclosed |
| US-8722660-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-05-13 | — | — | US | disclosed |
| US-20130029969-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-31 | — | — | US | disclosed |
| EP-2540728-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2013-01-02 | — | — | EP | disclosed |
| CN-102844320-A | Heterocyclic compounds | TAKEDA PHARMACEUTICAL | 2012-12-26 | — | — | CN | disclosed |
| US-20120277207-A1 | NOVEL HETEROCYCLIC ACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | FAB PHARMA S.A.S. (FR) | 2012-11-01 | — | — | US | disclosed |
| EP-2501693-A1 | NOVEL HETEROCYCLIC ACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | FAB Pharma SAS (FR) | 2012-09-26 | — | — | EP | disclosed |
| CN-102656158-A | Novel heterocyclic acrylamides and their use as pharmaceuticals | FAB PHARMA SAS | 2012-09-05 | — | — | CN | disclosed |
| WO-2011061214-A1 | NOVEL HETEROCYCLIC ACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | FAB PHARMA SAS (FR) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039553-A1 | CD73 COMPOUNDS | ENTPD5, ENTPD1, NT5E | HRH1 3975/4885SLC6A2 1082/4885HTR1A 1813/4885 |
| US-20130029969-A1 | HETEROCYCLIC COMPOUND | TP53, VHL, MGMT | HRH1 2686/4885SLC6A2 1336/4885HTR1A 4002/4885 |
| US-20240043427-A1 | CD73 COMPOUNDS | ENTPD5, ENTPD1, NT5E | HRH1 3975/4885SLC6A2 1082/4885HTR1A 1813/4885 |
| US-12110294-B2 | CD73 compounds | ENTPD5, ENTPD1, NT5E | HRH1 4005/4885SLC6A2 1027/4885HTR1A 1927/4885 |
| US-20230312542-A1 | HYDROXYPYRROLIDINE DERIVATIVE AND MEDICINAL APPLICATION THEREOF | VHL, MDM2, NEDD4 | HRH1 2293/4885SLC6A2 3543/4885HTR1A 3827/4885 |
| US-20140228352-A1 | HETEROCYCLIC COMPOUND | TP53, VHL, MGMT | HRH1 2686/4885SLC6A2 1336/4885HTR1A 4002/4885 |
| US-20140235615-A1 | HETEROCYCLIC COMPOUND | TP53, VHL, MGMT | HRH1 2686/4885SLC6A2 1336/4885HTR1A 4002/4885 |
| US-20120277207-A1 | NOVEL HETEROCYCLIC ACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | ACR, AADAC, AAAS | HRH1 726/4885SLC6A2 2836/4885HTR1A 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.